STOCK TITAN

Brainsway Ltd. Stock Price, News & Analysis

BWAY Nasdaq

Welcome to our dedicated page for Brainsway Ltd. news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. stock.

BrainsWay Ltd (BWAY) delivers innovative neurostimulation solutions through its FDA-cleared Deep TMS technology, offering noninvasive treatment for mental health disorders. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and corporate developments.

Access timely information about earnings reports, research collaborations, and therapeutic applications of Deep TMS technology. Our curated collection features official press releases and verified news covering treatment efficacy studies, global expansion efforts, and strategic partnerships.

Discover updates on BrainsWay's progress in addressing major depressive disorder, OCD, and addiction treatment through its patented magnetic stimulation platform. The resource serves investors monitoring neurotechnology trends and clinicians seeking evidence-based therapeutic innovations.

Bookmark this page for structured access to BWAY's latest developments in neuromodulation science and mental health treatment advancements. Stay informed about breakthrough clinical data and operational updates from this leader in noninvasive brain stimulation solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) announced a publication revealing impressive results from a post-marketing study on its Deep TMS™ treatment for depression. The study, featured in Psychiatry Research, involved 1,351 patients and demonstrated an 82% response rate and a 65% remission rate among those receiving 30 or more treatments. This data underscores the effectiveness of Deep TMS for patients who have previously failed over seven medication trials. With almost 75% of patients achieving remission based on the Hamilton Depression Rating Scale, the findings reinforce BrainsWay's commitment to advancing neurostimulation therapies for mental health disorders amidst a growing global mental health crisis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none

FAQ

What is the current stock price of Brainsway Ltd. (BWAY)?

The current stock price of Brainsway Ltd. (BWAY) is $16.06 as of September 17, 2025.

What is the market cap of Brainsway Ltd. (BWAY)?

The market cap of Brainsway Ltd. (BWAY) is approximately 319.5M.
Brainsway Ltd.

Nasdaq:BWAY

BWAY Rankings

BWAY Stock Data

319.49M
15.59M
6.39%
31.04%
1.01%
Medical Devices
Healthcare
Link
Israel
Jerusalem